HIV Community Planning: An evaluation of testing goals in six federally funded cities
Methods: Currently, CDC directly funds eight cities containing 37% of the HIV burden in the United States. Analyses were conducted on HIV funding for testing and planning data from 2010-2013, as well as jurisdictional plans and progress reports from six federally funded cities.
Results: Data from Los Angeles, San Francisco, Chicago, New York, Philadelphia, and Houston were analyzed to identify if HIV testing goals were met. The most common goals were expanded testing initiatives, targeted testing among priority populations, and implementation of routine, opt-out testing. Chicago consistently exceeded testing goals. Los Angeles and Houston increased testing events from 2010-2013, while San Francisco remained unchanged. New York, Philadelphia, and Chicago reduced their testing events from 2010-2013. Newly identified positive events decreased over time for each city.
Conclusion: Changes in HIV planning structure are projected to target priority populations more effectively. Overall, directly funded cities accomplished the goals of NHAS. Planning councils funding may contribute to early identification and reduction of new cases.
Learning Areas:Implementation of health education strategies, interventions and programs
Planning of health education strategies, interventions, and programs
Protection of the public in relation to communicable diseases including prevention or control
Evaluate the effectiveness of HIV detection and High Impact Prevention approaches from six CDC-funded cities on HIV testing events.
Keyword(s): HIV/AIDS, Planning
Qualified on the content I am responsible for because: I have worked within the Division of HIV/AIDS Prevention with the Centers for Disease Control and Prevention while conducting this analysis. This experiences culminated with a presentation to deputy directors within the division.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.